Bempedoic Acid: A New Drug for an Old Problem.

The Annals of Pharmacotherapy
Dat NguyenMatthew A Wanat

Abstract

To review the pharmacology, pharmacokinetics, safety, and efficacy of bempedoic acid for low-density lipoprotein cholesterol (LDL-C) reduction. A PubMed search was conducted from January 2000 to June 15, 2020, using the keyword bempedoic acid for phase III clinical trials published in the English language. Articles related to the Food and Drug Administration (FDA) approval of bempedoic acid and other trials relating to the safety and efficacy of this drug were included. The findings from this review show that bempedoic acid is a safe and effective option for lowering LDL-C levels in patients requiring LDL-C lowering for primary or secondary prevention of cardiovascular events. Statin therapy remains the mainstay of treatment for both primary and secondary prevention. However, many patients cannot tolerate statin therapy because of statin-associated muscle symptoms. Bempedoic acid may be a reasonable adjunct for LDL-C reduction, though further evaluation of cardiovascular outcomes with bempedoic acid in this population is needed. The recent FDA approval of bempedoic acid offers an additional option for lowering LDL-C levels in patients with atherosclerotic cardiovascular disease or heterozygous familial hyperlipidemia. Additiona...Continue Reading

References

Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Oct 12, 2016·International Journal of Cardiology·Maciej BanachPeter P Toth
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Apr 11, 2017·Journal of Clinical Lipidology·James M BackesPatrick M Moriarty
Oct 13, 2017·Circulation. Cardiovascular Quality and Outcomes·John N BoothEmily B Levitan
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Mar 14, 2019·The New England Journal of Medicine·Kausik K RayUNKNOWN CLEAR Harmony Trial
Mar 30, 2019·Journal of the American Heart Association·Ulrich LaufsErik S G Stroes

❮ Previous
Next ❯

Software Mentioned

CLEAR

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Drugs in Context
Joel C Marrs, Sarah L Anderson
Journal of Cardiovascular Pharmacology
Michael S KellyCraig J Beavers
Expert Opinion on Drug Metabolism & Toxicology
Arrigo F G CiceroIvan Cincione
© 2021 Meta ULC. All rights reserved